These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 24430917)

  • 1. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
    Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
    BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
    Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
    PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
    Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
    Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial.
    Lintzeris N; Bhardwaj A; Mills L; Dunlop A; Copeland J; McGregor I; Bruno R; Gugusheff J; Phung N; Montebello M; Chan T; Kirby A; Hall M; Jefferies M; Luksza J; Shanahan M; Kevin R; Allsop D;
    JAMA Intern Med; 2019 Sep; 179(9):1242-1253. PubMed ID: 31305874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial.
    Lintzeris N; Mills L; Dunlop A; Copeland J; Mcgregor I; Bruno R; Kirby A; Montebello M; Hall M; Jefferies M; Kevin R; Bhardwaj A;
    Drug Alcohol Depend; 2020 Oct; 215():108220. PubMed ID: 32768992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Pavlicova M; Brooks D; Glass A; Mahony A; Nunes EV; Bisaga A; Dakwar E; Carpenter KM; Sullivan MA; Choi JC
    Drug Alcohol Depend; 2016 Feb; 159():53-60. PubMed ID: 26711160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nabiximols as a substitute for cannabis].
    Dumont GJH
    Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33201625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
    Trigo JM; Lagzdins D; Rehm J; Selby P; Gamaleddin I; Fischer B; Barnes AJ; Huestis MA; Le Foll B
    Drug Alcohol Depend; 2016 Apr; 161():298-306. PubMed ID: 26925704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
    Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
    CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
    Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
    J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
    Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
    Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study.
    Winstock AR; Lea T; Copeland J
    J Psychopharmacol; 2009 Jan; 23(1):84-93. PubMed ID: 18515451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
    Mills L; Dunlop A; Montebello M; Copeland J; Bruno R; Jefferies M; Mcgregor I; Lintzeris N
    Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):67. PubMed ID: 36209081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
    Bethoux FA; Farrell R; Checketts D; Sahr N; Berwaerts J; Alexander JK; Skobieranda F
    Mult Scler Relat Disord; 2024 Sep; 89():105740. PubMed ID: 39106541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.
    Montebello M; Jefferies M; Mills L; Bruno R; Copeland J; McGregor I; Rivas C; Jackson MA; Silsbury C; Dunlop A; Lintzeris N;
    Drug Alcohol Depend; 2022 May; 234():109388. PubMed ID: 35316689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.
    Portenoy RK; Ganae-Motan ED; Allende S; Yanagihara R; Shaiova L; Weinstein S; McQuade R; Wright S; Fallon MT
    J Pain; 2012 May; 13(5):438-49. PubMed ID: 22483680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.